Pipeline

August 13, 2018
Company Drug/Device Medical Condition Status
OncoPep, Inc. PVX-410, investigational multi-peptide cancer vaccine Smoldering multiple myeloma (SMM) Phase Ib trial initiated
SW Safety Solutions, Inc. Nitrile Exam Gloves with Low Dermatitis Potential Claim Skin irritation or sensitization Initial – Looking for Principal Investigator to head clinical study
Kyowa Kirin, Inc. Poteligo (mogamulizumabkpkc) injection Relapsed or refractory mycosis fungoides (MF) or Sezary syndrome after at least one prior systemic therapy Approval granted by FDA
Celltrion, Inc. Bevacizumab biosimilar ‘CT-P16’ Metastatic colorectal cancer, metastatic breast cancer, non-small cell lung cancer, and glioblastoma Phase III trial initiated
Apotex Inc. New generic potassium chloride oral solution Hypokalemia (low potassium blood levels) in patients who are on diuretics Approval granted by the FDA under a novel term called the Competitive Generic Therapy designation
Alector, LLC AL001, a human recombinant monoclonal antibody Frontotemporal dementia (FTD) Granted Orphan Drug Designation by the FDA
Pliant Therapeutics, Inc. PLN-74809 Idiopathic pulmonary fibrosis (IPF) Granted Orphan Drug designation by the FDA
Castle Creek Pharmaceuticals, LLC Diacerein 1% ointment (CCP-020) Epidermolysis bullosa simplex (EBS) Fast Track Designation granted by the FDA
Elite Pharmaceuticals, Inc. Generic methadone hydrochloride 5 mg and 10 mg tablets Severe pain, maintenance treatment of opioid addiction (heroin or other morphine-like drugs) Approval granted by the FDA
Alteogen Inc. ALT-P7, an antibody-drug conjugate (ADC) using a Trastuzumab variant form of antibody Gastric cancer Granted Orphan Drug Designation by the FDA
Vertex Pharmaceuticals Inc. Orkambi (lumacaftor/ ivacaftor) Underlying cause of cystic fibrosis in children ages 2 to 5 with the most common form of the disease Approval granted by the FDA
BioCryst Pharmaceuticals, Inc. BCX7353 Prevention of angioedema attacks in patients with hereditary angioedema Fast Track Designation granted by the FDA
PharmaMar Lurbinectedin Small cell lung cancer Granted Orphan Drug Designation by the FDA
Sensus Healthcare, Inc. SRT-100+, the next-generation Superficial Radiation Therapy solution Non-melanoma skin cancers (NMSC) and keloids Granted 501(k) clearance by the FDA
Armagen Inc. GT-184, an investigational enzyme replacement therapy (ERT) Mucopolysaccharidosis type IIIA (also known as Sanfilippo Syndrome A or MPS IIIA) Granted Orphan Drug Designation by the FDA
Shionogi & Co., Ltd Mulpleta®(lusutrom-bopag) Thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure Approval granted by the FDA

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here